Trial Profile

Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zenocutuzumab (Primary)
Indications Adenocarcinoma; Liver metastases; Non-small cell lung cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Expanded access; Therapeutic Use
Sponsors Merus

Most Recent Events

20 May 2025 Status changed from recruiting to completed.
24 Oct 2023 Updated analysis demonstrating efficacy of Zenocutuzumab in patients (n=5) with previously treated advanced/metastatic NRG1+ PDAC were presented at the 48th European Society for Medical Oncology Congress
23 Oct 2023 According to a Merus media release, Interim data from this study presented at the European Society for Medical Oncology Congress (ESMO) Asia Congress 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com